Effect of different doses of ticagrelor on platelet response after percutaneous coronary intervention
Objective To analyze the effect of different doses of ticagrelor on platelet response after percutaneous coronary intervention(PCI).Methods A total of 128 patients with PCI admitted from February 2019 to May 2021 were selected as the research objects and divided into control group and observation group by random number table method,with 64 cases in each group.After PCI,the control group received high-dose ticagrelor treatment,and the observation group received low-dose ticagrelor treatment.The therapeutic effects of the two groups were compared.Results Before and after treatment,there were no significant differences in maximum platelet aggregation rate induced by arachidonic acid(AA-MAR),maximum platelet aggregation rate induced by adenosine diphosphate(ADP-MAR)and platelet aggregation rate(PAR)between the two groups(P＞0.05);after treatment,AA-MAR,ADP-MAR and PAR in the two groups were lower than those before treatment(P＜0.05).Follow up for 1 year,the total incidence of bleeding events in the observation group was 4.69%,which was lower than 15.63%in the control group(P＜0.05).Before and after treatment,there were no significant differences in coronary flow velocity reserve(CFVR),diastolic peak velocity(DPV),systolic peak velocity(SPV)and ciastolic time velocity integral(CTVI)between the two groups(P＞0.05);after treatment,CFVR,DPV,SPV and CTVI in the two groups were higher than those before treatment(P＜0.05).After treatment,the proportion of grade Ⅰ in the TIMI myocardial perfusion grade(TMPG)grading of the two groups was lower than that before treatment,and the proportion of grade Ⅱ and Ⅲ were higher than those before treatment(P＜0.05).Conclusion The use of ticagrelor after PCI can inhibit platelet aggregation and improve coronary blood flow and myocardial perfusion,and can also reduce the incidence of bleeding events with low-dose ticagrelor treatment.
万方数据
维普
